TABLE 2.

Summary of therapeutic evaluation of PG-11302 and fumagillin in SCID mice challenged with E. bieneusi spores

Mouse groupa	E. bieneusi spore challenge dose	Drug (dose [mg/kg/day])	% Inhibitionb
			At end of treatment with PG-11302	On the week following anti-IFN-γ antibody injection
1	0	PG-11302 (250)c	100	100
2	104	Placebo	0	0
3	104	Fumagillin (1)d	64.2	56.1
4	104	PG-11302 (250)	96.2	85.7
5	104	PG-11302 (125)e	69.4	28.7
6	104	PG-11302 (20)f	65.1	97.1

^aThere were six mice in each group.

^bPercent inhibition is the percent reduction in the average level of spore excretion in feces at the end of drug treatment and the week after the end of the experiment compared with the level of spore excretion in feces in the placebo-treated group.

^cPG-11302 was given orally once daily (250 mg/kg/day) for 7 days.

^dFumagillin was given orally once daily (1 mg/kg/day) for 7 days.

^ePG-11302 was given once orally daily (125 mg/kg/day) for 7 days.

^fPG-11302 was given i.p. daily over a week (20 mg/kg/injection).